Developmental anomaly of metabolic origin

Developmental anomaly of metabolic origin (Orphanet code 139009) is not a single disease but rather a broad classification category used in the Orphanet rare disease nomenclature. It encompasses a wide group of rare developmental disorders in which structural or functional anomalies arise as a consequence of an underlying inborn error of metabolism. In these conditions, disruption of specific metabolic pathways during embryonic or fetal development leads to malformations or developmental abnormalities affecting various organ systems, including the brain, skeleton, heart, eyes, and other tissues. Because this is a grouping term rather than a discrete clinical entity, the specific symptoms, inheritance patterns, age of onset, and severity vary enormously depending on the individual metabolic disorder involved. Examples of conditions that fall under this umbrella include Smith-Lemli-Opitz syndrome (a cholesterol biosynthesis defect causing multiple congenital anomalies), congenital disorders of glycosylation, peroxisomal disorders such as Zellweger spectrum disorders, and certain organic acidurias that produce developmental malformations. Each of these has its own genetic basis, clinical presentation, and management approach. Treatment strategies depend entirely on the specific underlying metabolic condition and may range from dietary modifications and cofactor supplementation to enzyme replacement therapy or organ transplantation. Early diagnosis through newborn screening, biochemical testing, and genetic analysis is critical for optimizing outcomes in many of these disorders. Genetic counseling is recommended for affected families given the hereditary nature of most conditions within this category.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Developmental anomaly of metabolic origin